Pharmaceutical composition for treating amyotrophic lateral sclerosis
AssigneesSapporo Medical University, Nipro Corporation
InventorsOsamu Honmou, Masanori Sasaki, Yuko Sasaki, Shinichi Oka, Masahito Nakazaki, Rie Maezawa
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pharmaceutical composition for treating amyotrophic lateral sclerosis. More specifically, the present invention relates to a pharmaceutical composition for treating amyotrophic lateral sclerosis, wherein the pharmaceutical composition comprises mesenchymal stem cells and is intravenously administered.
Claims9
A method for treating amyotrophic lateral sclerosis (ALS) comprising intravenously administering two or more doses of a therapeutically effective amount of mesenchymal stem cells derived from bone marrow or blood to a subject in need thereof, wherein the ALS is ALS in a moderate or severe stage corresponding to a stage in a rat ALS model with a Basso, Beattie and Bresnahan (BBB) score of 15 to 8, wherein 1.0×105 to 1.0×108 or more mesenchymal stem cells are administered in each dose,
- wherein the first administration is performed after the subject has developed clinical symptoms of ALS, and
- wherein the two or more doses are administered at intervals sufficient to maintain a therapeutic effect of a preceding dose.
Dependencies are inferred from the claim text.